Shots: The EC has approved Vimkunya (pre-filled syringe) against CHIKV disease in individuals (≥12yrs.) in 30 EEA states; launch expected in H1’25. MAA under the UK’s MHRA review with decision anticipated in H1’25 Approval was based on 2 P-III studies that met their 1EP of rapid immune response in 1wk. with ~97.8% of participants…

Shots: The CHMP has recommended Vimkunya (pre-filled syringe) against CHIKV disease in individuals (≥12yrs.), with the EC’s decision & launch expected in H1’25 for the EU, Iceland, Liechtenstein, & Norway Opinion was based on 2 P-III studies showing a rapid immune response in 1wk. with ~97.8% of participants (n=3,500) developing neutralizing antibodies by day…